These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31247042)

  • 1. Quality of life and outcomes in heart failure patients with ejection fractions in different ranges.
    Chen X; Xin Y; Hu W; Zhao Y; Zhang Z; Zhou Y
    PLoS One; 2019; 14(6):e0218983. PubMed ID: 31247042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.
    Yee D; Novak E; Platts A; Nassif ME; LaRue SJ; Vader JM
    Am J Cardiol; 2019 Mar; 123(5):807-812. PubMed ID: 30587373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF.
    Ahmeti A; Henein MY; Ibrahimi P; Elezi S; Haliti E; Poniku A; Batalli A; Bajraktari G
    BMC Cardiovasc Disord; 2017 Oct; 17(1):268. PubMed ID: 29041912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.
    Joseph SM; Novak E; Arnold SV; Jones PG; Khattak H; Platts AE; Dávila-Román VG; Mann DL; Spertus JA
    Circ Heart Fail; 2013 Nov; 6(6):1139-46. PubMed ID: 24130003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction.
    Napier R; McNulty SE; Eton DT; Redfield MM; AbouEzzeddine O; Dunlay SM
    JACC Heart Fail; 2018 Jul; 6(7):552-560. PubMed ID: 29885952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
    Farré N; Lupon J; Roig E; Gonzalez-Costello J; Vila J; Perez S; de Antonio M; Solé-González E; Sánchez-Enrique C; Moliner P; Ruiz S; Enjuanes C; Mirabet S; Bayés-Genís A; Comin-Colet J;
    BMJ Open; 2017 Dec; 7(12):e018719. PubMed ID: 29273666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction.
    Xin YG; Chen X; Zhao YN; Hu J; Sun Y; Hu WY
    Curr Med Res Opin; 2019 Apr; 35(4):561-568. PubMed ID: 30183419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
    Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome.
    Farmakis D; Simitsis P; Bistola V; Triposkiadis F; Ikonomidis I; Katsanos S; Bakosis G; Hatziagelaki E; Lekakis J; Mebazaa A; Parissis J
    Clin Res Cardiol; 2017 May; 106(5):359-368. PubMed ID: 27999929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction.
    Gastelurrutia P; Lupón J; Moliner P; Yang X; Cediel G; de Antonio M; Domingo M; Altimir S; González B; Rodríguez M; Rivas C; Díaz V; Fung E; Zamora E; Santesmases J; Núñez J; Woo J; Bayes-Genis A
    Mayo Clin Proc Innov Qual Outcomes; 2018 Jun; 2(2):176-185. PubMed ID: 30225447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Tsuji K; Sakata Y; Nochioka K; Miura M; Yamauchi T; Onose T; Abe R; Oikawa T; Kasahara S; Sato M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
    Eur J Heart Fail; 2017 Oct; 19(10):1258-1269. PubMed ID: 28370829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome.
    Faxén UL; Hage C; Donal E; Daubert JC; Linde C; Lund LH
    Int J Cardiol; 2018 Sep; 267():128-132. PubMed ID: 29957252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.
    Anker SD; Borggrefe M; Neuser H; Ohlow MA; Röger S; Goette A; Remppis BA; Kuck KH; Najarian KB; Gutterman DD; Rousso B; Burkhoff D; Hasenfuss G
    Eur J Heart Fail; 2019 Sep; 21(9):1103-1113. PubMed ID: 30652394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnaire].
    Garin O; Soriano N; Ribera A; Ferrer M; Pont A; Alonso J; Permanyer G;
    Rev Esp Cardiol; 2008 Mar; 61(3):251-9. PubMed ID: 18361898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiopulmonary exercise testing as prognostic indicators: Comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction.
    Sato T; Yoshihisa A; Kanno Y; Suzuki S; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Suzuki H; Saitoh SI; Ishida T; Takeishi Y
    Eur J Prev Cardiol; 2017 Dec; 24(18):1979-1987. PubMed ID: 29086584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.